Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

HMT in Women with LGSC of the Ovary or Peritoneum

J Clin Oncol; ePub 2017 Feb 21; Gershenson, et al

The addition of hormonal maintenance therapy (HMT) after primary treatment in women with stage II to IV low-grade serous carcinoma (LGSC) of the ovary or peritoneum significantly improved progression-free survival (PFS) rates compared with women who underwent routine observation (OBS), a recent study found. Patients had treatment with primary surgery followed by platinum-based chemotherapy, stage II to IV disease, at least 2 years of follow-up for those who had not experienced recurrence. Researchers found:

  • There were a total of 203 eligible patients (n=133 who underwent OBS; n=70 who received HMT).
  • Median PFS for patients who underwent OBS was 26.4 months compared with 64.9 months for those receiving HMT.
  • There was no statistically significant difference in overall survival (OS) between the 2 groups.
  • Women who received HMT had a significantly lower risk of disease progression vs those who underwent OBS (HR, 0.44).


Gershenson DM, Bodurka DC, Coleman RL, Lu KH, Malpica A, Sun CC. Hormonal maintenance therapy for women with low-grade serous cancer of the ovary or peritoneum. [Published online ahead of print February 21, 2017]. J Clin Oncol. doi:10.1200/JCO.2016.71.0632.